* Basado en 123 pacientes en un servicio ambulatorio para angioedema alemán de 1973 a 2001.²

1. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010;126(5):918-925;
2. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airwat obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229-1235;
3. Banerji A, Busse P, Christiansen SC, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc. 2015;36(3):213-217;
4. Bygum A, Aygören-Pürsün E, Beusterien K, et al. Burden Pf illness in hereditary angioedema: a conceptual model. Acta Derm Venereol. 2015;95(6):706-710;
5. Caballero T, Aygören-Pürsür E, Bygum A, et al. The humanistic bUrden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc. 2014;35(1):47-53;
6. Maurer M, Magerl M, Ansotegui I, et al. The Internacional WAO/EAACI guideline for the management of hereditary angioedema-the 2017 revision and upload. Allergy. 2018, 73(8):1575-1596;
7. Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. 2018;320(20):2108-2121.